Rakesh Popat Selected Research

belantamab mafodotin

12/2023	Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
9/2023	Patient-Reported Outcomes With Belantamab Mafodotin Treatment in Patients With Triple-Class Refractory Multiple Myeloma.
1/2023	Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
1/2022	High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
11/2021	DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
1/2021	Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).
12/2020	Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
12/2020	Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody-Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study.
1/2020	Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
1/2020	Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rakesh Popat Research Topics

Disease

54	Multiple Myeloma 01/2024 - 06/2005
8	Neoplasms (Cancer) 01/2024 - 10/2007
7	Immunoglobulin Light-chain Amyloidosis 01/2022 - 01/2018
5	Infections 10/2023 - 01/2020
4	Disease Progression 07/2023 - 12/2016
4	Neutropenia 01/2023 - 10/2007
4	Thrombocytopenia (Thrombopenia) 01/2021 - 10/2007
3	Hypertension (High Blood Pressure) 02/2023 - 01/2020
2	Lymphoma (Lymphomas) 01/2023 - 11/2021
2	B-Cell Lymphoma (Lymphoma, B Cell) 01/2023 - 01/2020
2	Amyloidosis 09/2020 - 01/2020
1	Plasmacytoma 09/2023
1	Fatigue 09/2023
1	Pain (Aches) 09/2023
1	Lymphopenia (Lymphocytopenia) 02/2023
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2023
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2023
1	Hypophosphatemia 01/2023
1	Body Weight (Weight, Body) 11/2022
1	Sepsis (Septicemia) 11/2022
1	COVID-19 09/2022
1	Hyperglycemia 11/2021
1	Hematologic Neoplasms (Hematological Malignancy) 09/2021
1	Hemolytic Anemia 01/2021
1	Thrombosis (Thrombus) 01/2021
1	Thrombotic Microangiopathies 01/2021
1	Asymptomatic Infections 01/2021
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2020
1	Pneumonia (Pneumonitis) 12/2020
1	Septic Shock (Toxic Shock Syndrome) 12/2020
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Necrosis 12/2018
1	Residual Neoplasm 11/2018
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2013

Drug/Important Bio-Agent (IBA)

22	Bortezomib (Velcade)FDA Link 02/2023 - 06/2005
20	Dexamethasone (Maxidex)FDA LinkGeneric 09/2023 - 06/2005
12	belantamab mafodotinIBA 12/2023 - 12/2018
9	Lenalidomide (CC 5013)FDA Link 09/2023 - 01/2015
7	Melphalan (Alkeran)FDA LinkGeneric 07/2023 - 10/2007
7	Immunoconjugates (Immunoconjugate)IBA 01/2023 - 12/2018
6	B-Cell Maturation AntigenIBA 10/2023 - 12/2018
6	Proteasome InhibitorsIBA 11/2022 - 12/2018
5	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 10/2023 - 12/2018
4	daratumumabIBA 10/2023 - 01/2018
4	carfilzomibIBA 02/2023 - 12/2019
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 06/2005
4	PanobinostatIBA 12/2020 - 12/2016
3	pomalidomideIBA 09/2023 - 01/2017
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2023 - 01/2021
3	Histone Deacetylase InhibitorsIBA 01/2018 - 10/2013
2	Chimeric Antigen ReceptorsIBA 01/2024 - 01/2021
2	Bispecific AntibodiesIBA 01/2024 - 10/2023
2	Immunomodulating AgentsIBA 11/2022 - 01/2020
2	Amyloid (Amyloid Fibrils)IBA 01/2022 - 01/2020
2	ixazomibIBA 01/2021 - 01/2020
2	Monoclonal AntibodiesIBA 09/2020 - 01/2020
2	AntigensIBA 09/2020 - 12/2018
2	Thalidomide (Thalomid)FDA Link 01/2019 - 12/2016
1	Surface Antigens (Surface Antigen)IBA 01/2024
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2023
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 09/2023
1	Tyrosine (L-Tyrosine)FDA Link 01/2023
1	Syk KinaseIBA 01/2023
1	Interleukin-2 (IL2)IBA 01/2023
1	Amylases FDA Link 01/2023
1	LigandsIBA 01/2023
1	fms-Like Tyrosine Kinase 3IBA 01/2023
1	isatuximabIBA 11/2022
1	iberdomideIBA 11/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 11/2021
1	TOR Serine-Threonine KinasesIBA 11/2021
1	Hypoglycemic Agents (Hypoglycemics)IBA 11/2021
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 11/2021
1	Insulin (Novolin)FDA Link 11/2021
1	talazoparibIBA 09/2021
1	Cytotoxins (Cytolysins)IBA 01/2021
1	RO6870810IBA 01/2021
1	Lysine (L-Lysine)FDA Link 12/2020
1	Histone DemethylasesIBA 12/2020
1	venetoclaxIBA 12/2020
1	TAK-659IBA 01/2020
1	Alkylating AgentsIBA 12/2018
1	Cell Surface ReceptorsIBA 12/2018
1	monomethylauristatin FIBA 12/2018
1	Immunologic Factors (Immunomodulators)IBA 12/2018
1	RNA (Ribonucleic Acid)IBA 11/2018
1	Biomarkers (Surrogate Marker)IBA 12/2017

Therapy/Procedure

18	Therapeutics 10/2023 - 06/2005
8	Stem Cell Transplantation 07/2023 - 10/2007
4	Drug Therapy (Chemotherapy) 09/2022 - 10/2007
2	Immunotherapy 01/2024 - 10/2023
2	Transplantation 02/2023 - 10/2007
1	Subcutaneous Injections 11/2022
1	Treatment Delay 09/2022
1	Salvage Therapy 01/2021
1	Premedication 01/2021
1	Immunomodulation 01/2021
1	Resistance Training 01/2020
1	Intravenous Infusions 01/2020
1	Drug Tapering 01/2017